ZERFLUITY Trademark

Trademark Overview


On Friday, September 23, 2022, a trademark application was filed for ZERFLUITY with the United States Patent and Trademark Office. The USPTO has given the ZERFLUITY trademark a serial number of 97604595. The federal status of this trademark filing is SECOND EXTENSION - GRANTED as of Monday, September 16, 2024. This trademark is owned by Pfizer Inc.. The ZERFLUITY trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use
zerfluity

General Information


Serial Number97604595
Word MarkZERFLUITY
Filing DateFriday, September 23, 2022
Status731 - SECOND EXTENSION - GRANTED
Status DateMonday, September 16, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 22, 2023

Trademark Statements


Goods and ServicesPharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, October 11, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 100012192

Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 100012192

Trademark Events


Event DateEvent Description
Tuesday, September 27, 2022NEW APPLICATION ENTERED
Tuesday, October 11, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, March 28, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, March 28, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, March 28, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, July 7, 2023ASSIGNED TO EXAMINER
Friday, July 14, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, August 22, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, August 2, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 22, 2023PUBLISHED FOR OPPOSITION
Tuesday, October 17, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, March 8, 2024SOU EXTENSION 1 FILED
Friday, March 8, 2024SOU EXTENSION 1 GRANTED
Friday, March 8, 2024SOU TEAS EXTENSION RECEIVED
Saturday, March 9, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, September 16, 2024SOU TEAS EXTENSION RECEIVED
Monday, September 16, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, September 16, 2024SOU EXTENSION 2 FILED
Monday, September 16, 2024SOU EXTENSION 2 GRANTED